Biocon To Buy Back GE Shares In Syngene Unit
This article was originally published in PharmAsia News
Executive Summary
Biocon said it would buy GE Capital's 7.69% stake in its research unit for $3.5 billion as part of the India biotech's plan to take Syngene public.